Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024
October 22 2024 - 4:30PM
Business Wire
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries,
announced today that it will issue financial results for the third
quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m.
(ET).
Conference call and webcast: The Company will host a
conference call and webcast at 8:30 a.m. (ET) on Tuesday, November
5, 2024, to discuss financial results. During the call, management
will refer to a slide presentation which will be available on the
morning of the call on the “Financial Results” page under the
Company's Investor Relations section of its website.
Pre-registration: Participants who pre-register will be
given a conference passcode and unique PIN to gain immediate access
to the call and bypass the live operator. Participants are
encouraged to pre-register for the conference call using the
following link: STVN conference call pre-registration.
Webcast: A live, listen-only webcast of the call will be
available at the following link: STVN Q3 2024 Webcast
Dial in: Those who are unable to pre-register may dial in
by calling:
Italy:
+39 02 802 09 11
United Kingdom:
+44 1 212 818004
United States:
+1 718 705 8796
United States Toll Free:
+1 855 265 6958
Questions during the call: Participants who wish to ask
questions during the call should use the HD webphone link:
https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=
Replay:
The webcast will be archived for three months on the Investor
Relations section of the Company’s website.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions, as well
as engineering solutions to the pharmaceutical, biotechnology and
life sciences industries. Stevanato Group delivers an integrated,
end-to-end portfolio of products, processes and services that
address customer needs across the entire drug lifecycle from
development to clinical and commercial stages. Stevanato Group’s
core capabilities in scientific research and development, its
commitment to technical innovation and its engineering excellence
are central to its ability to offer value-added solutions to
clients. For more information, please visit
www.stevanatogroup.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241022517591/en/
Investor Relations Lisa Miles
lisa.miles@stevanatogroup.com
Media media@stevanatogroup.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Dec 2023 to Dec 2024